IdeS: Phase II started

Hansa began an open-label, U.K. Phase II trial to evaluate single doses of 0.25 and 0.5 mg/kg IV IdeS in up to 6 patients with acquired TTP and low ADAMTS13 activity who are asymptomatic. ...